Related Experiment Video
Updated: Jun 19, 2026
07:22
A High-throughput Cre-Lox Activated Viral Membrane Fusion Assay to Identify Inhibitors of HIV-1 Viral Membrane Fusion
Published on: August 14, 2018
Current peptide HIV type-1 fusion inhibitors
Wei Pang1, Siu-Cheung Tam, Yong-Tang Zheng
1Key Laboratory of Animal Models and Human Diseases Mechanisms, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming, Yunnan, China.
Antiviral Chemistry & Chemotherapy
|October 2, 2009
Summary
New fusion inhibitor peptides show promise for HIV-1 therapy, offering more potent activity and improved resistance profiles compared to existing drugs like enfuvirtide (T20). These advancements are crucial for developing next-generation AIDS therapeutics.
Area of Science:
- Virology
- Drug Discovery
- Immunology
Background:
- Current antiretroviral drugs, while effective, present challenges including toxic side effects and the emergence of drug-resistant HIV-1 strains.
- Understanding HIV-1 gp41 structure and the viral entry mechanism has paved the way for rationally designed fusion inhibitors.
- Enfuvirtide (T20), a synthetic polypeptide fusion inhibitor, marked a significant advancement but has limitations such as susceptibility to degradation and resistance development.
Purpose of the Study:
- To review recent developments in fusion inhibitory peptides for anti-HIV-1 therapy.
- To highlight novel peptides with enhanced potency and different mechanisms of action compared to enfuvirtide (T20).
- To assess the potential of these new compounds as future therapeutic agents against HIV-1 infection.
Main Methods:
- Review of scientific literature on HIV-1 fusion inhibitors and peptide development.
- Analysis of structural and functional data of emerging fusion inhibitory peptides.
- Evaluation of antiviral activity and resistance profiles of novel peptide candidates.
Main Results:
- Numerous promising fusion inhibitory peptides have been developed, demonstrating potent antiviral activities against HIV-1.
- Some novel peptides exhibit improved characteristics over enfuvirtide (T20), including enhanced stability and activity.
- These peptides represent a new generation of potential therapeutic agents with diverse mechanisms to combat HIV-1 replication.
Conclusions:
- New fusion inhibitory peptides offer a promising avenue for overcoming the limitations of current HIV-1 therapies.
- These agents have the potential to be developed into effective treatments, addressing drug resistance and side effects.
- Continued research into peptide-based fusion inhibitors is essential for advancing AIDS therapeutics.
Related Concept Videos
01:19Inhibitors of Virion Maturation and Assembly
As part of their replication cycle, certain viruses synthesize long precursor proteins called polyproteins within infected host cells. In human immunodeficiency virus (HIV), two major polyproteins are produced: Gag and Gag-Pol. The Gag polyprotein supplies the structural components of the virus, while Gag-Pol includes essential viral enzymes such as reverse transcriptase, integrase, and protease. After synthesis, these polyproteins move to the host cell membrane, where they assemble into an...
01:22Antiviral Nucleoside Inhibitors
Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...
01:30Inhibitors of Viral Protein Synthesis
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
01:10Retrovirus Life Cycles
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
01:25Inhibitors Of Virion Release
Viral replication and dissemination rely on efficient mechanisms for host cell entry, genome replication, assembly, and release. Influenza viruses, such as types A and B, are negative-sense single-stranded RNA viruses with a segmented genome, that depend on two critical surface glycoproteins to carry out these processes: hemagglutinin (HA) and neuraminidase (NA). HA initiates infection by binding to sialic acid residues on the surface of host epithelial cells, facilitating receptor-mediated...
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...